$0.99
1.98% day before yesterday
Nasdaq, Jun 28, 10:00 pm CET
ISIN
CA6823108759
Symbol
ONCY
Sector
Industry

Oncolytics Biotech Inc. Share price

$0.99
-0.11 10.00% 1M
-0.37 27.21% 6M
-0.36 26.67% YTD
-1.43 59.09% 1Y
-1.83 64.89% 3Y
-0.71 41.76% 5Y
-11.17 91.86% 10Y
Nasdaq, Closing price Fri, Jun 28 2024
ISIN
CA6823108759
Symbol
ONCY
Sector
Industry

Key figures

Market capitalization $75.09m
Enterprise Value $54.04m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 4.40
Turnover (TTM) Turnover $0.00
EBIT (operating result TTM) EBIT $-26.54m
Free cash flow (TTM) Free cash flow $-20.67m
Cash position $21.88m
EPS (TTM) EPS $-0.30
P/E ratio expected negative
P/S ratio expected 85.52
EV/Sales expected 61.54
Short interest 0.95%
Show more

Is Oncolytics Biotech Inc. a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.

Oncolytics Biotech Inc. Share analysis

Unlock scores for free

Analyst opinions

7 Analysts have issued a Oncolytics Biotech Inc. forecast:

7x Buy
100%

Analyst opinions

7 Analysts have issued a Oncolytics Biotech Inc. forecast:

Buy
100%

Financial data from Oncolytics Biotech Inc.

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
- -
-
100%
- Direct costs 0.32 0.32
7% 7%
-
-0.32 -0.32
7% 7%
-
- Selling and administrative expenses 11 11
31% 31%
-
- Research and development costs 15 15
28% 28%
-
-26 -26
29% 29%
-
- Depreciation and amortization 0.32 0.32
7% 7%
-
EBIT (operating result) EBIT -27 -27
29% 29%
-
Net profit -21 -21
14% 14%
-

Figures in millions USD.

Don't miss a thing! We will send you all news about the Oncolytics Biotech Inc. share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Oncolytics Biotech Inc. Share News

Neutral
PRNewsWire
3 days ago
Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report overall survival results from the randomized HR+/HER2- metastatic breast cancer BRACELET-1 trial in H2 2024 SAN DIEGO and CALGARY, AB , June 27, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company s...
Neutral
PRNewsWire
6 days ago
Wayne Pisano, Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast cancer study continues to be expected in H2 2024 Pelareorep combination therapy advancing towards registration-enabling study in pancreatic cancer SAN DIEGO and CALGARY, AB , June 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinic...
Neutral
PRNewsWire
10 days ago
Demonstrating pelareorep's synergy with modified FOLFIRINOX +/- atezolizumab in pancreatic cancer could expand the number of patients it may benefit Funding for the study comes from the US$5 million Therapeutic Accelerator Award from PanCAN SAN DIEGO, and CALGARY, AB , June 20, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing...
More Oncolytics Biotech Inc. News

Company profile

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

Head office Canada
CEO Wayne Pisano
Employees 27
Founded 1998
Website www.oncolyticsbiotech.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now